PROTALIX BIOTHERAPEUTICS, INC. (PLX)

[Kronberg]

Protalix Biotherapeutics (NYSE:PLX), a novel enzyme innovator operating in the orphan disease market. Accordingly, the stock traded $0.03 higher at $0.47 for 6.8% profits. Despite powering multiple enzyme replacement therapies (ERTs) as shown in figure 2, the market seemed pessimistic about the company’s fortunes. One key reason is the subpar sales of the sole approved therapeutic, taliglucerase alfa (Uplyso) for gaucher’s disease. Another concern is the lack of robustness in the early clinical data for the cystic fibrosis franchise. Be that as it may, our research revealed that there are substantial prospects in the Fabry disease segment. And, the stock can trade much higher when the company will release the interim data for the phase 3 (BALANCE) trial studying PRX-102 for Fabry treatment (sometimes this year).

Protalix shareholders have a favorable chance of hitting a big payday when the firm releases the BALANCE trial interim data sometimes this year.

https://seekingalpha.com/article/4163043-rounds-report-nephros-protalix-bulls-charged-ahead-crispr-insiders-built-shares